You are here

Roche receives EU approval for Gazyvaro, European approval for Actemra

2017-07-05T204623Z_1785941188_RC1FBB5B1DC0_RTRMADP_3_HEALTH-CANCER-VACCINES.JPG
Roche said it has received European approval for its Actemra medication in giant cell arteritis (GCA), the Swiss drugmaker said on Friday.

[ZURICH] Roche said it has received European approval for its Actemra medication in giant cell arteritis (GCA), the Swiss drugmaker said on Friday.

"As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to fundamentally change how this condition is treated," Sandra Horning, Roche's chief medical officer and global head of product development, said in a statement.

In a separate statement, Basel-based Roche said it also received European Union approval of Gazyvaro for people with previously untreated advanced follicular lymphoma.

REUTERS

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes